Abera Bioscience initiates collaboration with an American university to accelerate the development of a vaccine candidate based on the company’s latest vaccine platform comprising protein bodies.
The study will be conducted in vivo and will provide a first indication of applicability outside of the pneumococcal area. The cost profile for protein body-based vaccine formulations is very good, which would be a strong advantage in the intended area.
“Joint interests in research opened up a fantastic opportunity to, in a cost-effective and resource-saving way, carry out further studies on our newly developed vaccine candidate together with our partner. We look forward to gaining new knowledge about how our platform can be used in the future, and anticipate positive results that may lead to further collaborations ,” says Maria Alriksson, CEO of Abera Bioscience.
The study will begin in the fourth quarter.